Therapeutics stocks beat Q1 revenue estimates by 14.5%

Earnings

โดย Yahoo Finance·Read original

Summary · why it matters

The 11 therapeutics stocks tracked by this publication reported a satisfactory first quarter, with aggregate revenues beating analysts' consensus estimates by 14.5%. Myriad Genetics posted revenues of $200.4 million, up 2.3% year on year but missing expectations by 1%, while Moderna delivered the fastest revenue growth among its peers with $389 million, a 260% increase that exceeded estimates by 55.8%. United Therapeutics was the weakest performer against analyst estimates, with revenues of $781.5 million down 1.6% year on year and missing by 1.9%. Amgen reported $8.62 billion in revenues, up 5.8% and beating estimates by 1.4%, and BioMarin Pharmaceutical recorded $766.2 million, up 2.8% but lagging expectations by 1.3%. Since their latest earnings results, therapeutics stocks have seen share prices rise 14% on average.